Literature DB >> 9927212

Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.

C Caron de Fromentel1, N Gruel, C Venot, L Debussche, E Conseiller, C Dureuil, J L Teillaud, B Tocque, L Bracco.   

Abstract

We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3. 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421. The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53 -/-human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present. Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53 -/- human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927212     DOI: 10.1038/sj.onc.1202338

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain.

Authors:  Angeli Möller; Emmanuelle Pion; Vikram Narayan; Kathryn L Ball
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

Review 2.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

3.  Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.

Authors:  Liang Li; Christopher S Gondi; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 4.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

5.  Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.

Authors:  Carsten J Kirschning; Stefan Dreher; Björn Maass; Sylvia Fichte; Jutta Schade; Mario Köster; Andreas Noack; Werner Lindenmaier; Hermann Wagner; Thomas Böldicke
Journal:  BMC Biotechnol       Date:  2010-04-13       Impact factor: 2.563

Review 6.  Intrabody and Parkinson's disease.

Authors:  Chun Zhou; Serge Przedborski
Journal:  Biochim Biophys Acta       Date:  2008-09-12

7.  Bicistronic DNA display for in vitro selection of Fab fragments.

Authors:  Takeshi Sumida; Nobuhide Doi; Hiroshi Yanagawa
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

8.  CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity.

Authors:  Stefan Tanner; Alcide Barberis
Journal:  J Negat Results Biomed       Date:  2004-11-17

9.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002

Review 10.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.